These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32832590)

  • 1. Blood-based biomarkers for Alzheimer's pathology and the diagnostic process for a disease-modifying treatment: Projecting the impact on the cost and wait times.
    Mattke S; Cho SK; Bittner T; Hlávka J; Hanson M
    Alzheimers Dement (Amst); 2020; 12(1):e12081. PubMed ID: 32832590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimates of Current Capacity for Diagnosing Alzheimer's Disease in Sweden and the Need to Expand Specialist Numbers.
    Mattke S; Gustavsson A; Jacobs L; Kern S; Palmqvist S; Eriksdotter M; Skoog I; Winblad B; Wimo A; Jönsson L
    J Prev Alzheimers Dis; 2024; 11(1):155-161. PubMed ID: 38230728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood-based biomarkers in Alzheimer's disease: Future directions for implementation.
    Suridjan I; van der Flier WM; Monsch AU; Burnie N; Baldor R; Sabbagh M; Vilaseca J; Cai D; Carboni M; Lah JJ
    Alzheimers Dement (Amst); 2023; 15(4):e12508. PubMed ID: 38058357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caregivers' attitudes toward blood-based biomarker testing for Alzheimer's disease.
    Bolsewig K; Blok H; Willemse EAJ; Zwaaftink RBMG; Kooistra M; Smets EMA; Teunissen CE; Visser LNC
    Alzheimers Dement (Amst); 2024; 16(1):e12549. PubMed ID: 38371360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparedness of the Brazilian health-care system to provide access to a disease-modifying Alzheimer's disease treatment.
    Mattke S; Corrêa Dos Santos Filho O; Hanson M; Mateus EF; Neto JPR; de Souza LC; Rizek Schultz R; Pereira Pinto R
    Alzheimers Dement; 2023 Jan; 19(1):375-381. PubMed ID: 36063494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Capacity for Diagnosing Alzheimer's Disease in Germany and Implications for Wait Times.
    Mattke S; Tang Y; Hanson M; von Arnim CAF; Frölich L; Grimmer T; Onur OA; Perneczky R; Teipel S; Thyrian JR
    J Alzheimers Dis; 2024; 101(4):1249-1259. PubMed ID: 39302379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expected wait times for access to a disease-modifying Alzheimer's treatment in England: A modelling study.
    Mattke S; Tang Y; Hanson M
    J Health Serv Res Policy; 2024 Apr; 29(2):69-75. PubMed ID: 37931615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expected wait times for access to a disease-modifying Alzheimer's treatment in the United States.
    Mattke S; Hanson M
    Alzheimers Dement; 2022 May; 18(5):1071-1074. PubMed ID: 34569686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimated Investment Need to Increase England's Capacity to Diagnose Eligibility for an Alzheimer's Treatment to G7 Average Capacity Levels.
    Mattke S; Shi Z; Hanson M; Mitchell S; Lynch C; MacLean Kalonji K; Lanman L
    J Prev Alzheimers Dis; 2024; 11(4):1022-1029. PubMed ID: 39044513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI).
    Arevalo-Rodriguez I; Smailagic N; Roqué I Figuls M; Ciapponi A; Sanchez-Perez E; Giannakou A; Pedraza OL; Bonfill Cosp X; Cullum S
    Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010783. PubMed ID: 25740785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying treatment in Alzheimer's disease--a simulation study.
    Sköldunger A; Johnell K; Winblad B; Wimo A
    Curr Alzheimer Res; 2013 Feb; 10(2):207-16. PubMed ID: 23036018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is Korea Prepared for an Alzheimer's Disease-Modifying Therapy? Assessing the Korean Healthcare System Infrastructure and the Effect of Blood-Based Biomarker Tests.
    Jun H; Cho SK; Yoong J; Mattke S
    Ann Geriatr Med Res; 2021 Mar; 25(1):33-38. PubMed ID: 33550774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic performance of a combination of Mini-Mental State Examination and Clock Drawing Test in detecting Alzheimer's disease.
    Kato Y; Narumoto J; Matsuoka T; Okamura A; Koumi H; Kishikawa Y; Terashima S; Fukui K
    Neuropsychiatr Dis Treat; 2013; 9():581-6. PubMed ID: 23662057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost of treatment of Alzheimer's disease in The Netherlands: a regression-based simulation model.
    McDonnell J; Redekop WK; van der Roer N; Goes E; Ruitenberg A; Busschbach JJ; Breteler MM; Rutten FF
    Pharmacoeconomics; 2001; 19(4):379-90. PubMed ID: 11383754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Florbetapir-PET in Alzheimer's Disease: A Spanish Societal Perspective.
    Hornberger J; Michalopoulos S; Dai M; Andrade P; Dilla T; Happich M
    J Ment Health Policy Econ; 2015 Jun; 18(2):63-73. PubMed ID: 26231002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the Cost-effectiveness of a Hypothetical Disease-modifying Therapy With Limited Duration for the Treatment of Early Symptomatic Alzheimer Disease.
    Boustani M; Doty EG; Garrison LP; Smolen LJ; Belger M; Klein TM; Murphy DR; Burge R; Wall JK; Johnston JA
    Clin Ther; 2022 Nov; 44(11):1449-1462. PubMed ID: 36210219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of MMSE with VSRAD and eZIS has greater accuracy for discriminating mild cognitive impairment from early Alzheimer's disease than MMSE alone.
    Tokumitsu K; Yasui-Furukori N; Takeuchi J; Yachimori K; Sugawara N; Terayama Y; Tanaka N; Naraoka T; Shimoda K
    PLoS One; 2021; 16(2):e0247427. PubMed ID: 33617587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Projected Savings to Canadian Provincial Budgets from Reduced Long-Term Care Home Utilization Due to a Disease-Modifying Alzheimer's Treatment.
    Jun H; Shi Z; Mattke S
    J Prev Alzheimers Dis; 2024; 11(1):179-184. PubMed ID: 38230731
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.